GlassScriptPhysician profile
Ali Kazemi
NPI 1346567781
$740.19
in general payments reported to CMS, 2019-2025
9 companies · $437 in 2025
The $437 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.69 · 2021: $140 · 2022: $19.50 · 2023: $62.37 · 2024: $34.87 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $313.15 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.20 | 2020-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $95.33 | 2021-2025 | Gattex |
| Braintree Laboratories, INC. | $50.46 | 2024-2025 | Suflave, Sutab |
| Janssen Biotech, INC. | $41.19 | 2023 | Simponi Aria, Remicade, Stelara |
| Celgene Corporation | $40.68 | 2022-2023 | Zeposia |
| Ethicon US, LLC | $38.49 | 2021 | |
| Abbvie INC. | $19.99 | 2025 | |
| Daiichi Sankyo INC. | $19.70 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Kazemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.